Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature.
BPDCN
Bcl-2
Blastic plasmacytoid dendritic cell neoplasm
Venetoclax
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
26 Jun 2021
26 Jun 2021
Historique:
received:
22
01
2021
accepted:
01
06
2021
entrez:
26
6
2021
pubmed:
27
6
2021
medline:
30
6
2021
Statut:
epublish
Résumé
We describe a patient with blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement and the outcome of venetoclax use in this setting. A 54-year-old Caucasian male was referred to the Haematology Unit with an enlarged inguinal lymph node which was diagnostic of a blastic plasmacytoid dendritic cell neoplasm. The staging revealed disseminated disease (skin, visceral, lymph nodes, and bone marrow). He received chemotherapy with an acute myeloid leukaemia-like regime. Afterwards, he underwent allogeneic haematopoietic stem cell transplantation, though it was not successful, showing a relapse 14 months later with hepatic and central nervous system dissemination. Intrathecal chemotherapy was administered, and venetoclax (anti-bcl2 agent) was started in an off-label indication based on most recent literature. The disease halted its course for 3 months. In the end, the patient's disease progressed and so he succumbed due to infectious complications. Venetoclax monotherapy seems not enough to control the disease progression under CNS involvement and other treatments should be investigated.
Sections du résumé
BACKGROUND
BACKGROUND
We describe a patient with blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement and the outcome of venetoclax use in this setting.
CASE PRESENTATION
METHODS
A 54-year-old Caucasian male was referred to the Haematology Unit with an enlarged inguinal lymph node which was diagnostic of a blastic plasmacytoid dendritic cell neoplasm. The staging revealed disseminated disease (skin, visceral, lymph nodes, and bone marrow). He received chemotherapy with an acute myeloid leukaemia-like regime. Afterwards, he underwent allogeneic haematopoietic stem cell transplantation, though it was not successful, showing a relapse 14 months later with hepatic and central nervous system dissemination. Intrathecal chemotherapy was administered, and venetoclax (anti-bcl2 agent) was started in an off-label indication based on most recent literature. The disease halted its course for 3 months. In the end, the patient's disease progressed and so he succumbed due to infectious complications.
CONCLUSIONS
CONCLUSIONS
Venetoclax monotherapy seems not enough to control the disease progression under CNS involvement and other treatments should be investigated.
Identifiants
pubmed: 34172079
doi: 10.1186/s13256-021-02939-7
pii: 10.1186/s13256-021-02939-7
pmc: PMC8235836
doi:
Substances chimiques
Bridged Bicyclo Compounds, Heterocyclic
0
Sulfonamides
0
venetoclax
N54AIC43PW
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
326Références
Ann Hematol. 2020 Apr;99(4):907-909
pubmed: 32030448
Mol Ther. 2017 Aug 2;25(8):1933-1945
pubmed: 28479045
J Oncol Pharm Pract. 2021 Jun;27(4):990-995
pubmed: 32847479
Blood. 2014 Jul 17;124(3):385-92
pubmed: 24859366
Br J Haematol. 2017 Dec;179(5):781-789
pubmed: 28980314
Blood. 2019 Aug 22;134(8):678-687
pubmed: 31243042
Leuk Res. 2019 Oct;85:106199
pubmed: 31415942
Haematologica. 2019 May;104(5):e222-e223
pubmed: 30765472
Curr Treat Options Oncol. 2019 Feb 4;20(1):9
pubmed: 30715612
N Engl J Med. 2018 Oct 11;379(15):1479-1481
pubmed: 30304659
Cancer Discov. 2017 Feb;7(2):156-164
pubmed: 27986708
N Engl J Med. 2019 Apr 25;380(17):1628-1637
pubmed: 31018069
Blood Adv. 2018 Apr 24;2(8):848-858
pubmed: 29661755
Medicine (Baltimore). 2017 Dec;96(51):e9452
pubmed: 29390581
Am J Hematol. 2018 Mar;93(3):401-407
pubmed: 29218851